Alzheimer’s drugs ‘make no meaningful difference to patients’, say researchers

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s (Alamy/PA) -

Drugs that are said to slow the progression of Alzheimer’s disease “make no meaningful difference to patients” while increasing the risk of swelling and bleeding in the brain, according to a new review.

The effects of the medicines on those with early-stage Alzheimer’s and dementia were “either absent or consistently small”, researchers said.